Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $11.9000 (-2.02%) ($11.9000 - $11.9000) on Thu. Feb. 18, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.02% (three month average) | RSI | 18 | Latest Price | $11.9000(-2.02%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -10.1% a day on average for past five trading days. | Weekly Trend | FOLD declines -16.5% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(53%) IWO(49%) XBI(49%) IWM(46%) IWC(44%) | Factors Impacting FOLD price | FOLD will decline at least -2.51% in a week (0% probabilities). VIXM(-28%) VXX(-13%) UUP(-11%) UNG(-6%) IGOV(-2%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.51% (StdDev 5.02%) | Hourly BBV | -0.5 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-13.45(-213.03%) | Resistance Level | $18.07 | 5 Day Moving Average | $13.48(-11.72%) | 10 Day Moving Average | $16.42(-27.53%) | 20 Day Moving Average | $18.07(-34.14%) | To recent high | -52.2% | To recent low | 0% | Market Cap | $3.073b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |